reports
- Jonathan Moreland
Sangamo Therapeutics Inc: 2 directors
Two Directors at Sangamo Therapeutics Inc sold 415,769 shares at between 0.253USD and 0.258USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...
- Jonathan Moreland
- Jonathan Moreland
- Jonathan Moreland
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten O...
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the pricing of its underwritten offering of 18,018,014 shares of its voting common stock (the “Common Stock”) at a price of $4.44 per share, and, in lieu of Common Stock to investors who so chose, pre-funded warrants to purchase up to 2,252,252 shares of its Common Stock at a price of $4.4399 per pre-funded warrant, which ...
Prelude Therapeutics Presents Preclinical Data from Development Candid...
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 Data Demonstrate Potential for Differentiated Efficacy and Safety Profile, Including Complete Responses as Monotherapy in Multiple CDX and PDX Models of HR+/HER2- Breast Cancer Prelude Remains on Track to File Investigational New Drug (IND) Application by mid-2026 and to initiate clinical trial in 2H 2026 WILMINGTON, Del., April 20, 2026 (GLOBE NEWSWIR...
- Jonathan Moreland
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D....
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer WILMINGTON, Del., April 15, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude Therapeutics” or the “Company”), a clinical-stage precision oncology company, today announced that Dr. Charles Morris will join the Company as Chief Medical Officer effective, April 20, 2026. “We are thrilled to welcome Dr. Charles Morris to Prelude Therapeutics as Executive Vice President and Chief Medical Officer,” stated Kris Vaddi, Chief Executive Officer of Prelude Therapeutics....
- Jonathan Moreland
CTAS CINTAS CORPORATION
BZUN BAOZUN INC SPONSORED ADR CLASS A
NMM NAVIOS MARITIME PARTNERS
SPT SPROUT SOCIAL
DNA INC.
TOI GINKGO BIOWORKS HOLDINGS
SMR INC.
GF ONCOLOGY INSTITUTE INC (THE)
MESO NUSCALE POWER CORP
COE THE NEW GERMANY FUND
INC.
MESOBLAST LIMITED
COLUMBIA EQUITY TRUST
INC.
- Jonathan Moreland
PCF PUTNAM HIGH INCOME SECURITIES FUND
CRT CROSS TIMBERS ROYALTY TRUST
LW LAMB WESTON HOLDINGS INC.
RPAY REPAY HOLDINGS (A)
CNXC CONCENTRIX
SG SWEETGREEN INC
CWBC COMMUNITY WEST BANCSHARES NEW
MXF THE MEXICO FUND
GF INC.
BETR THE NEW GERMANY FUND
ACET INC.
BETTER HOME & FINANCE HOLDING COMPANY
ADICET BIO INC
- Jonathan Moreland
- Jonathan Moreland
LULU LULULEMON ATHLETICA INC
NMM NAVIOS MARITIME PARTNERS
RPAY REPAY HOLDINGS (A)
AIMD.P AIM4 VENTURES
RBLX ROBLOX
QS QUANTUMSCAPE
ZI ZOOMINFO TECHNOLOGIES INC
ECAT BLACKROCK ESG CAP ALLOCATION TR
NRXS NEURAXIS INC
MXF THE MEXICO FUND
GF INC.
NFJ THE NEW GERMANY FUND
INC.
NFJ DIVIDEND
INTEREST & PREMIUM STRATEGY FUND
- Jonathan Moreland
ALT ALTIMMUNE INC
PX P10 INC
TSM TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
NRGV ENERGY VAULT HOLDINGS INC
SBSW SIBANYE-STILLWATER LTD
POCI PRECISION OPTICS CORP INC (MASS)
MXF THE MEXICO FUND
GF INC.
AFCG THE NEW GERMANY FUND
TNXP INC.
AFC GAMMA
INC.
TONIX PHARMACEUTICALS HOLDING CORP.
- Jonathan Moreland
HTGC HERCULES CAPITAL INC.
FMNB FARMERS NATIONAL BANC CORP.
GAM GENERAL AMERICAN INVESTORS CO. INC.
WVE WAVE LIFE SCIENCES
TSI TCW STRATEGIC INCOME FUND INC.
STIM STIMSONITE CORP
GO GROCERY OUTLET HOLDING
AHCO ADAPTHEALTH
GTLB GITLAB INC
TSM TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
MXF THE MEXICO FUND
GF INC.
AFCG THE NEW GERMANY FUND
VERO INC.
AFC GAMMA
INC.
VENUS CONCEPT INC
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Qua...
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in study, which U.S. Food and Drug Administration (FDA) reiterated in October may serve as primary basis of approval under Accelerated Approval pathway Rolling submission of Biologics License Agreement (BLA) to FDA seeking ST-920 approval is in progress Transit...
- Jonathan Moreland
PANW PALO ALTO NETWORKS INC.
OSUR ORASURE TECHNOLOGIES INC.
FMNB FARMERS NATIONAL BANC CORP.
NXRT NEXPOINT RESIDENTIAL TRUST INC.
LULU LULULEMON ATHLETICA INC
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
CRT CROSS TIMBERS ROYALTY TRUST
KYN KAYNE ANDERSON MLP INVESTMENT CO.
INSE INSPIRED ENTERTAINMENT
NEPH NEPHROS INC
NEXT NEXTDECADE
AXR AMREP
KOD KODIAK SCIENCES
NMM NAVIOS MARITIME PARTNERS
REEMF RARE ELEMENT RESOURCES
RPAY REPAY HOLDINGS (A)
AHCO ADAPTHEALTH
ADV ADVANTAGE SOLUTIONS INC (A)
PX P10 INC
AIRS AIRSCULPT TECHNOLOGIES INC
BORR BORR DRILLING LTD
TPST MILLENDO THERAPEUTICS
KMPH INC.
IAUX KEMPHARM INC
SBSW I-80 GOLD CORP.
MNR SIBANYE-STILLWATER LTD
TLPH MACH NATURAL RESOURCES LP
MXF TALPHERA INC.
IBIO THE MEXICO FUND
GF INC.
AFCG IBIO INC.
FMBM THE NEW GERMANY FUND
GSM INC.
AFC GAMMA
INC.
F & M BANK CORP
GLOBE SPECIALTY METALS INC.
- Jonathan Moreland
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Pr...
ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights PRECISE-AD Phase 1b trial fully enrolled. Completion of six-month assessments expected in Q2 2026 with blinded interim analysis anticipated early Q3 2026; twelve-month top-line data anticipated in early 2027 PMN310 continues to demonstrate a favorable safety profile, with no treatment-related serious adverse events reported to date Cambridge, Massachusetts,, March 25, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on th...
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.